Cargando…

Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T‐cell lymphomas

Immune checkpoints, including PD‐1/PD‐L1, play an important role in immunosuppression in various malignancies. Elevated levels of soluble programmed death ligand 1 (sPD‐L1) are associated with worse prognosis in multiple myeloma and diffuse large B cell lymphoma. Herein, the purpose of this study is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xuhan, Liu, Lu, Zhou, Shiyong, Zhao, Kuo, Song, Zheng, Hu, Ge, Zhang, Tingting, Li, Yang, Qiu, Lihua, Li, Lanfang, Qian, Zhengzi, Meng, Bin, Pan, Yi, Ren, Xiubao, Wang, Xianhuo, Zhang, Huilai, Fu, Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771895/ https://www.ncbi.nlm.nih.gov/pubmed/31074879 http://dx.doi.org/10.1002/hon.2636

Ejemplares similares

Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients
por: Fei, Yue, et al.
Publicado: (2020)

Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma
por: Li, Yang, et al.
Publicado: (2021)

Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
por: Qu, Zhenjie, et al.
Publicado: (2022)

Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3(+) CD8(+) T Cells and Survival in Diffuse Large B Cell Lymphoma
por: Zhang, Tingting, et al.
Publicado: (2020)

Corrigendum to “Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3(+) CD8(+) T Cells and Survival in Diffuse Large B Cell Lymphoma”
por: Zhang, Tingting, et al.
Publicado: (2021)

Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China
por: Gao, Fenghua, et al.
Publicado: (2022)

m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment
por: Zhang, Tingting, et al.
Publicado: (2022)

PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B‐cell lymphoma
por: Zhang, Huilai, et al.
Publicado: (2022)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma
por: Wu, Zizheng, et al.
Publicado: (2021)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
por: Zhang, Tingting, et al.
Publicado: (2022)

An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy
por: Lu, Yaxiao, et al.
Publicado: (2021)

Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer
por: Zhao, Peiqi, et al.
Publicado: (2021)

Pan-Cancer Analysis Reveals Genomic and Clinical Characteristics of TRPV Channel-Related Genes
por: Wang, Xiaoxuan, et al.
Publicado: (2022)

A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
por: Zhao, Peiqi, et al.
Publicado: (2021)

Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy
por: Zhao, Peiqi, et al.
Publicado: (2021)

A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma
por: Qiu, Lihua, et al.
Publicado: (2022)

Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy
por: Zhao, Peiqi, et al.
Publicado: (2022)

Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma
por: Qian, Zhengzi, et al.
Publicado: (2015)

Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells
por: Dong, Ling, et al.
Publicado: (2016)

A Phase I Trial to Evaluate the Multiple-Dose Safety and Antitumor Activity of Ursolic Acid Liposomes in Subjects with Advanced Solid Tumors
por: Qian, Zhengzi, et al.
Publicado: (2015)

A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma
por: Wang, Xiaoxuan, et al.
Publicado: (2022)

Overexpression of microRNA-130a predicts adverse prognosis of primary gastrointestinal diffuse large B-cell lymphoma
por: Chen, Leiyuan, et al.
Publicado: (2020)

miR-150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B-cell lymphoma
por: Wang, Xinyuan, et al.
Publicado: (2020)

Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57(CDKN1C) and TP53INP1 in mantle cell lymphoma
por: Li, Wei, et al.
Publicado: (2019)

Characteristics and outcomes of non-Hodgkin’s lymphoma patients with leptomeningeal metastases
por: Meng, Xiangrui, et al.
Publicado: (2018)

High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
por: Guo, Xiaofang, et al.
Publicado: (2018)

Genome-wide mutational signatures revealed distinct developmental paths for human B cell lymphomas
por: Ye, Xiaofei, et al.
Publicado: (2020)

Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas
por: Bi, Chengfeng, et al.
Publicado: (2017)

The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review
por: Zhang, Lanfang, et al.
Publicado: (2020)

Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors
por: Liu, Min, et al.
Publicado: (2020)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma
por: HAN, LIJUAN, et al.
Publicado: (2014)

Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome
por: Li, Shuping, et al.
Publicado: (2022)

Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer
por: Sun, Jin, et al.
Publicado: (2020)

Membrane Fas Ligand Kills Human Peripheral Blood T Lymphocytes, and Soluble Fas Ligand Blocks the Killing
por: Suda, Takashi, et al.
Publicado: (1997)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2022)

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
por: Chang, Boyang, et al.
Publicado: (2018)

Diagnosis of mediastinal cysts: the role and safety of EUS–FNA with 19-gauge needle: a retrospective cohort study
por: Cao, Fuliang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iiqu7adojvlvko5i80lgj5p7ti